MedTrace Logo

Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment

NCT04143282 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2021-12-07

No results posted yet for this study

Summary

This study aims to determine the effect of metformin along with standard cancer treatment, and its effect on the prognosis of the metastatic breast in non-diabetic patients.

Conditions

Interventions

DRUG

Metformin plus chemotherapy

determine the effect of metformin along with standard chemotherapy

DRUG

Chemotherapy

standard chemotherapy

Sponsors & Collaborators

  • Hager salah el din

    lead OTHER

Principal Investigators

  • ahmed a berry, PhD · Faculty of Medicine, Beni Suef University

  • ahmed h shaaban, MD · Faculty of Medicine, Beni Suef University

  • hoda m rabea, PhD · Faculty of pharmacy, Beni Suef University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-20
Primary Completion
2020-04-20
Completion
2020-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04143282 on ClinicalTrials.gov